Sarepta Therapeutics, Inc. (SRPT) Stock

Sarepta Therapeutics, Inc. (SRPT) is a Healthcare stock trading at $18.79 (as of 2026-08-21), with a market capitalization of $1.98B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on therapies for rare genetic diseases, including RNA-targeted treatments and gene therapies. It markets EXONDYS 51 and VYONDYS 53 for Duchenne muscular dystrophy based on specific dystrophin gene exon-skipping mutations, and is developing additional programs for related targets.

Understand Sarepta Therapeutics, Inc.: how it makes money

Sarepta Therapeutics develops and sells RNA-targeted therapeutics and gene therapies for rare diseases, including EXONDYS 51 and VYONDYS 53, and makes money through net product revenue from its approved therapies and collaboration-related revenues.

Sarepta’s profit potential is driven by a mix of net product revenue from approved therapies and a large non-cash collaboration revenue item related to Roche’s program option decline.

Revenue by segment (latest quarter)
Approved Therapies	$0.3B
Roche Non-Cash (Option Decline)	$0.3B
Collaboration and Other	$0.0B

Business quality (Strong): High operating profitability in the latest quarter, but quarterly results are meaningfully influenced by a non-cash collaboration revenue line item alongside product sales across specific therapy franchises.

Valuation: At 48× earnings, SRPT trades 186% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

Strong operating profitability: Operating margin was 49.0% for the period ended 2026-03-31.
Material contribution from a key product: Net product revenue from Elevitus was 0.38B USD.
Substantial product and collaboration mix: Net product revenue from approved therapies was 0.33B USD, and non-cash collaboration revenue related to the Roche program option decline was also 0.33B USD.

Bear case

Non-cash collaboration revenue may be volatile: Non-Cash Collaboration Revenue Related to Roche Program Option Decline was 0.33B USD in the latest quarter, which could vary in future periods.
Limited visibility from royalties in this quarter: Royalty Revenue was 0.0B USD for the period ended 2026-03-31.
Revenue depends on specific approved therapy franchises: Several therapy-related net product revenue line items are small in the provided breakdown (for example, Net Product Revenue from Vyondys 53 Franchise was 0.03B USD).

Valuation — source: SEC EDGAR (first-party)
Price	$18.79
Market Cap	$1.98B
EV / EBITDA	15.5
Price / Book	1.32
Price / Sales	0.80
FCF Yield	-83.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$2.20B
Net Margin	-32.5%
Revenue Growth (YoY)	15.6%
EPS Growth (YoY)	-388.7%
FCF Growth (YoY)	-10.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.02 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($321.07M)
Institutional Holders Tracked	10
Congressional Trades (recent)	7

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Douglas S. Ingram
Employees	1,372
Country	US
IPO Date	1997-06-04

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.